Skip to main content
SpringerLink
Log in

Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Rsf-1 (HBXAP) was recently reported to be overexpressed in various cancers and associated with the malignant behavior of cancer cells. However, the expression of Rsf-1 and its clinical significance in human hepatocellular carcinoma (HCC) have not been reported. In the present study, we analyzed the expression pattern of Rsf-1 in human HCC tissues and found that Rsf-1 was overexpressed in 41.1 % of HCC specimens. There was a significant association between Rsf-1 overexpression and tumor stage (p = 0.0322), AFP (p = 0.0184), and tumor relapse (p = 0.0112). Furthermore, Rsf-1 overexpression correlated with poor overall survival in HCC patients (p < 0.001). Rsf-1 overexpression could serve as an independent predictor for poor recurrence-free survival (p = 0.0079). Small interfering RNA (siRNA) knockdown in SK-Hep-1 cells with high endogenous Rsf-1 expression inhibited cell proliferation and colony formation, with downregulation of cyclin E protein. In conclusion, Rsf-1 is overexpressed in HCCs and serves as a novel tumor marker. Rsf-1 contributes to hepatocellular carcinoma cell growth through regulation of cell cycle proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S206–14.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  4. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373–82.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 2001;34(4 Pt 1):707–13.

    Article  CAS  PubMed  Google Scholar 

  6. Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, et al. Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res. 2011;17(1):46–55.

    Article  CAS  PubMed  Google Scholar 

  7. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(2):275–81.

    Article  CAS  PubMed  Google Scholar 

  8. Zhao ZK, Dong P, Gu J, Chen L, Zhuang M, Lu WJ, et al. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumour Biol. 2013;34(1):173–80.

    Article  PubMed  Google Scholar 

  9. Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103(3):814–9.

    Article  CAS  PubMed  Google Scholar 

  10. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102(39):14004–9.

    Article  PubMed  Google Scholar 

  11. Huang X, Gollin SM, Raja S, Godfrey TE. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002;99(17):11369–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Li Q, Dong Q, Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun. 420(1):6–10.

  13. Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 33(5):1485–91.

  14. Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229(4):559–68.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196(2):1010–6.

    Article  CAS  PubMed  Google Scholar 

  16. Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer. 1999;80(12):2034–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Wong N, Lai P, Pang E, Fung LF, Sheng Z, Wong V, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res. 2000;6(10):4000–9.

    CAS  PubMed  Google Scholar 

  18. Davidson B, Wang TL, Shih Ie M, Berner A. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol. 2008;39(4):616–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32(5):931–9.

    Article  CAS  PubMed  Google Scholar 

  20. Davis PK, Brackmann RK. Chromatin remodeling and cancer. Cancer Biol Ther. 2003;2(1):22–9.

    Article  PubMed  Google Scholar 

  21. Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002;12(1):73–9.

    Article  CAS  PubMed  Google Scholar 

  22. Wolffe AP. Chromatin remodeling: why it is important in cancer. Oncogene. 2001;20(24):2988–90.

    Article  CAS  PubMed  Google Scholar 

  23. Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 2006;14(4):381–3.

    Article  CAS  PubMed  Google Scholar 

  24. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2006;100(2):264–70.

    Article  CAS  PubMed  Google Scholar 

  25. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007;26(49):6997–7005.

    Article  CAS  PubMed  Google Scholar 

  26. Cheng CK, Chow LW, Loo WT, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 2005;65(19):8646–54.

    Article  CAS  PubMed  Google Scholar 

  27. Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer. 1993;67(5):1122–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 2000;17(1):103–6.

    CAS  PubMed  Google Scholar 

  29. Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 178(5):2407–15.

  30. Endo M, Yasui K, Zen Y, Gen Y, Zen K, Tsuji K, et al. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int. 2013;33(1):105–17.

    Article  CAS  PubMed  Google Scholar 

  31. Zhong R, Liu L, Tian Y, Wang Y, Tian J, Zhu BB, et al. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis. Sci Rep. 2014;4:4147.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YT, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 285(49):38260–9.

  33. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Bei’er Road 92, Heping District, Shenyang, Liaoning Province, People’s Republic of China

    Chengyao Xie, Lin Fu, Lingling Xie, Nan Liu & Qingchang Li

Authors
  1. Chengyao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingling Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qingchang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qingchang Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, C., Fu, L., Xie, L. et al. Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma. Tumor Biol. 35, 7595–7601 (2014). https://doi.org/10.1007/s13277-014-2008-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2008-8

Keywords

Search

Navigation